

A Use of Medicinal Plant with Transfersome as a Vesicular Carrier that Increase the Permeation

**Mr. Vaibhavkumar Bapu Bhagwat¹, Miss. Mayuri Jagtap²,
Mr. Onkar B. Doke³, Miss. Priyanka K. Shinde⁴**

¹Assistant Professor, Department of Pharmaceutics, Vidya Niketan College of Pharmacy, Lakhewadi, Tal- Indapur, Dist- Pune (MH), 413103, India

²Final Year Student, Vidya Niketan College of Pharmacy, Lakhewadi, Tal- Indapur, Dist- Pune (MH), 413103, India

³Associate Professor, Department of Pharmaceutics, Vidya Niketan College of Pharmacy, Lakhewadi, Tal- Indapur, Dist- Pune (MH), 413103, India

⁴Assistant Professor, Department of Pharmacognosy, Vidya Niketan College of Pharmacy, Lakhewadi, Tal- Indapur, Dist- Pune (MH), 413103, India

Abstract

The goal of the study was to create Transfersomes, a unique vesicular carrier with improved anti-inflammatory effects by lowering the gastrointestinal toxicity linked to oral administration. Phospholipids, extract from medicinal plants, and transfersomes made by Thin Film Hydration Techniques employing surfactants are some of the components of medicinal plants that are used in varying proportions. Particle size, entrapment efficiency, zeta potential, in vitro drug release, and transmission electron microscopy were assessed for the prepared Transfersomes. Using Fourier transform infrared spectroscopy [FT-IR], the compatibility between the medicinal plant extract and the excipients was assessed, and they were found to be compatible. Vesicle size was observed in the batch Transfersomes that were optimized. The best batch formulations of Transfersomes were mixed with polymer and tested for drug content, pH, spreadability, and in vitro penetration against commercial products. Compared to branded formulation, the deformed vesicle formed formulation performs better when combined with edge activator. Transfersome formulations containing medicinal plant extract have been found to offer a higher permeation rate than commercial formulations, based on parameters such as extract of medicinal plant release that were analyzed.

Keywords: Transfersomes¹, Deformable and Ultra Vesicles², Medicinal Plant³, Edge Activators⁴, phosphatidylcholine⁵, Stratum Corneum⁶.

1. Introduction

The totality of transfersome is complicated, highly adaptive, and stress-responsive. It is preferred as a very deformable vesicle with a lipid bilayer complex encircling a waterless core. The lipid bilayer's structure and shape enable the vesicle to regulate and optimize tone. This Transfer some facilitates the effective traversal of many wall types and serves as a medication carrier for the targeted, non-invasive administration of medication and the continuous release of restorative chemicals. Also known as

transfersomes or elastic vesicles, these are malleable, flexible vesicles. [Figure 1]. Phospholipid vesicles known as transfersomes are valuable transdermal drug delivery vehicles. Owing to their incredibly flexible membrane and tone-optimized packets, they can carry the medication into or through the skin hedge with great effectiveness, depending on the mode of administration. Transfersomes' vesicular system is more elastic than that of perfect liposomes, making it better suited for skin penetration. Transfersomes compress themselves together with the stratum corneum's intracellular sealing lipid to lessen the position of skin penetration problem. [1, 2]




Fig 1- Structure of Transfersome

By improving the solubilization of hydrophobic medications, the Edges Activators included in transfersomal formulation can also increase the medication's effectiveness [3,4,5]. Skin permeability is enhanced by the edge activators' capacity to solubilize and fluidize lipids [6, 7]. The type and concentration of edge activators determine their effective involvement in skin permeability. Surfactants function as penetrating enhancers and edge activators [8]. The vesicular structure's lipophilic and hydrophilic characteristics provide transfersomes a very wide range of solubility [9, 10, 11].

1.1 Advantages of transfersomes [12, 13, 14, 15]

- The hydrophilic and hydrophobic parts of transfersome carriers combine to provide a special medication carrier system that can administer therapeutic drugs with a broad spectrum of solubility.
- Because of their elastic packages and ultra-deformability, transfersomes can fit through the condensation of the skin barrier in very thin spaces that are five to ten times smaller than the vesicle periphery.
- High vesicle deformability allows for both topical and systemic therapies by facilitating the passage of medications through the skin without any detectable loss of whole vesicles.
- Almost any type of agent, regardless of size, structure, molecular weight, or resistance, can be accommodated by transfersome carriers, which are genuinely versatile.
- They are completely biocompatible and biodegradable because they are composed of naturally occurring phospholipids and edge activators.

- Key/main active components, such as proteins and peptides, insulin, corticosteroids, interferons, anaesthetics, NSAIDs, anticancer medications, and herbal remedies, can be delivered via transfersomes.
- Preventing first-pass metabolism, a significant disadvantage of oral medication administration, and maximising the drug's bioavailability
- The fact that they are manufactured with pharmaceutically acceptable ingredients and conventional forms is a plus, but they must be planned and optimized on a case-by-case basis.
- The product technique is brief and straightforward, making it simple to scale up significantly.

1.2 Limitations of transfersomes [12, 13, 16]

- Transfersomes' propensity for oxidative decline makes them chemically unstable. When the waterless medium is degassed and cleaned using inert gases, such as nitrogen and argon, the oxidation of Transfersomes can be greatly reduced [17]. Oxidation risk can also be decreased by low temperature storage and light protection [18]. Similar to spray- and snap-drying, post-preparation processing can improve Transfersomes' storage stability [19].
- A further drawback of using Transfersomes as a drug delivery mechanism is how hard it is to make natural phospholipids chaste. Consequently, druthers made of synthetic phospholipids might be employed [20].
- The cost of transfersomal phrasings is related to the raw materials needed to make lipid excipients and the pricey equipment needed to boost production. Phosphatidylcholine is therefore an often used lipid ingredient due to its relatively low cost [21].

1.3 Mechanism of action:

Colloidal patches, sometimes referred to as vesicles, are waterless cubes composed of amphiphilic motes that are encased in a concentric bilayer. They serve as incredibly helpful vesicular drug delivery systems, delivering hydrophilic drugs that are reabsorbed in the interior waterless cube while hydrophobic drugs become entangled in the lipid bilayer [22]. They are new medicine carrier vesicles that are largely deformable (ultra-flexible) and tone-optimizing; their ability to pass through the skin is mostly dependent on the Transfersomes, membrane inflexibility, hydrophilicity, and vesicle integrity [Fig.2] [23, 24].




Fig.2- The mechanism of action of transfersomes.

When applied in non-occlusive conditions, they effectively penetrate the entire skin; this particular non-occlusive state of the skin is significantly required to start a trans-epidermal bibulous grade across the epidermis [25, 26]. Because of the humidity evaporating from the transfersomal expression after its operation on the skin (a non-occlusive condition), transfersomes have a tendency to seek out deeper skin layers rather than a dry exterior background [27]. Alcohols (ethanol or propylene glycol) are utilized in small amounts in transfersome formulations as cosolvents with strong solvating ability and as penetration enhancers. It has been suggested that ethanol can cause changes to the polar head area of the lipid bilayer. Ethanol penetrates cells, enhances the intercellular lipid matrix's fluidity, and eventually causes the lipid vesicles' viscosity to decrease [28]. Transfersomes can enter the target areas, such as the dermis and blood circulation, by passing through the stratum corneum. Their ability to penetrate is contingent upon the transfersomal membrane's deformability, which is a result of the compositions of the vesicles [29, 30]. For each therapeutic drug, the most appropriate vesicle compositions must therefore be connected through collaboratively devised experimental techniques in order to provide the most appropriate carriers with the best deformability, medicine carrying capacity, and stability.

1.4 Need of the study.

- To make low-permeable medications more permeable.
- To determine whether the excipients are compatible with pharmaceutical drugs that is active and has low permeability.
- To demonstrate that the prepared product's quality and effect are superior to those of the marketed product, respectively.

2. Composition of transfersomes

Transfersomes are generally composed of,

- The primary component was initially an amphipathic component (such as phosphatidylcholine from soya or egg) that could be an admixture of lipids, which are the vesicle-forming elements that create the lipid bilayer [31, 32].
- Secondly, surfactants/edge activators i.e. sodium cholates, sodium deoxycholate, Tweens and Spans (Tween 20, Tween 60, Tween 80, Span 60, Span 65, and Span 80), and dipotassium glycyrrhizinate are the most often used edge activators in transfersome medications. These biocompatible bilayer-softening composites improve the permeability and increase the bilayer inflexibility of the vesicles [33, 34, 35, 36, and 37].
- A saline phosphate buffer (pH 6.5–7) or water should eventually be used as the hydration medium and detergent, together with three to ten alcohol (ethanol or methanol) [38, 39].

3. Preparation Methodology

3.1 Rotary Evaporation-Sonication Method /Thin Film Hydration Technique

Thin film hydration technique with rotary evaporation-sonication method- In a beaker with a circular bottom, the phospholipids and edge activator (components that form vesicles) are dissolved using an erratic mixture of organic detergent (for example, methanol and chloroform at an appropriate (v/v) rate). This stage can include the incorporation of the lipophilic medication. A rotary vacuum evaporator is used to fade the organic detergent above the lipid transition temperature under reduced pressure in order to generate a thin layer. Sustain it under Hoover to get rid of any remaining detergent residue.

Additionally, the deposited thin film is drenched by gyrating for a second time at the appropriate temperature, employing a buffer result with the suitable pH (illustration pH 7.4). At this point, the objectification of hydrophilic medicines can be completed. To obtain tiny vesicles, the performing vesicles are inflated at room temperature and sonicated in a bath or inquiry sonicator. Extrusion across a sandwich of 200 nm to 100 nm polycarbonate membranes homogenizes the sonicated vesicles [12, 40].

3.2 Vortex-Sonication Method

In a phosphate buffer, the medication, edge activator, and phospholipids are combined. In order to get milky transfersomal suspense, the mixture is additionally vortexed. In addition, it is extruded through polycarbonate membranes (illustrations 450 and 220 nm) and sonicated once more at ambient temperature using a bath sonicator [41, 42].

3.3 Modified Handshaking System

The rotating evaporation-sonication system and the modified handshaking system both operate on the same basic idea. The organic detergent, lipophilic medication, phospholipids, and edge activator are added to a round-bottom beaker during the modified handshaking procedure. The detergent should completely dissolve each excipient, yielding a translucent, clear end product. Additionally, rather than employing a rotational vacuum evaporator, the organic detergent is eliminated by evaporation while shaking hands. Meanwhile, the water bath is kept at a high temperature (40 to 60 °C) with the round-bottom beaker partially submerged. Within the beaker wall, a thin lipid coating also forms. The detergent is allowed to completely evaporate in the beaker over night.

3.4 Reverse-Phase Evaporation Method-

In a round-bottom beaker, the phospholipids and edge activator are combined and dissolved in the organic detergent mixture (diethyl ether and chloroform, for example). This stage can include the incorporation of the lipophilic medication. In order to obtain the lipid flicks, the detergent is also faded using a rotary evaporator. In the organic phase, which is primarily made up of isopropyl ether and/or diethyl ether, the lipid flicks are redissolved. A two-phase system is created later when the organic phase and the waterless phase are combined. At this point, the objectification of hydrophilic medicines can be completed. To create a homogenous w o (water in oil painting) conflation, this system is additionally subjected to sonication utilising a bath sonicator. Using a rotary evaporator, the organic detergent is slowly fading to create a thick gel that eventually forms a vesicular suspension [41, 42].

3.5 Ethanol Injection Method

The phospholipid, edge activator, and lipophilic medication are dissolved in ethanol with glamorous shifting for a distinctive amount of time, till a distinct outcome is obtained, to create the organic phase. The water-answerable materials are dissolved in the phosphate buffer to create the waterless phase. At this point, the objectification of hydrophilic medicines can be completed. Both outcomes are heated to between 45 and 50 °C. Afterwards, uninterrupted shifting is used to fit the ethanolic phospholipid result dropwise into the waterless result for a different time. The process of ethanol junking involves sonicating to reduce particle size and moving the attendant dissipation into a vacuum evaporator [43, 44].

4. Characterization of transfersomes

4.1 Size, Zeta Potential, and Morphology of Vesicles

One of the key variables in drug transfer, batch-to-batch comparison, and scale-up procedures is the vesicle size. The vesicle size fluctuation during storage is a significant factor affecting the expression's physical stability. More than 40 nm-sized vesicles are vulnerable to emulsion processes because Size, Zeta Potential, and Morphology of Vesicles. One of the key variables in drug transfer, batch-to-batch comparison, and scale-up procedures is the vesicle size. The vesicle size fluctuation during storage is a significant factor affecting the expression's physical stability. One element influencing the ability of the medication composites in transfersomes to be synopsized is vesicle size. A higher waterless core volume is desired for the encapsulation of hydrophilic composites, whereas a higher lipid-to-core rate is preferred for lipophilic and amphiphilic agents. The vesicle periphery can generally be established using the dynamic light scattering (DLS) method or photon correlation spectroscopy (PCS). The suspense of the vesicle can be combined with a suitable medium, and triplet vesicular size measurements are possible. Additionally, the sample can be produced in distilled water and filtered through a membrane sludge measuring 0.2 mm as an alternative method. In order to determine the size of the vesicles using DLS or PCS, the filtered sample is also contaminated with filtered saline. Additionally, the size and size distribution of vesicles can be determined using the Malvern Zetasizer motorised inspection system connected to the DLS system, while transmission electron microscopy (TEM) is employed to detect structural changes. Using the Malvern Zetasizer, the electrophoretic mobility fashion measures the zeta eventuality. Phase discrepancy microscopy or transmission electron microscopy (TEM) can be used to visualise transfersome vesicles [45, 46].

4.2 Entrapment Efficiency (%EE)

The quantum of medicine entangled in the statement is called the ruse effectiveness (EE). The untrapped medication is extracted from the vesicles utilising colourful techniques akin to mini-column centrifugation in order to calculate the EE. To find the EE in this procedure, direct or circular methods can be applied. The direct method would involve ultracentrifugation, supernatant removal, and vesicle dismemberment using an appropriate detergent capable of lysing the deposition. In order to eliminate contaminations, the performance result can now be tampered with and filtered through a hype sludge (0.22-0.45 μm). Using logical techniques, such as spectrophotometry or modified high-performance liquid chromatography (HPLC), which rely on the logical system of the active pharmaceutical component (API), the medication content is ascertained.[47, 48, 49]

The percentage of drug entrapment is written as:

$$(\text{Total Drug} + \text{Supernatant Drug}) / (\text{Total Drug}) \times 100\% \quad (1)$$

This is the formula for Drug Entrapment Efficiency.

4.3 Degree of Deformability

This parameter is significant because it influences the transfersomal expression's saturation. Pure water is used as the standard in this investigation. Numerous microporous contaminants with known severance sizes ranging from 50 to 400 nm are exposed to the medication. DLS (Dynamic Light Scattering) measurements are used to record the flyspeck size and size distribution following each pass [46, 50]. The expression for the degree of deformability is

$$D = J (rv/rp) 2 \quad (2)$$

J is the suspension's weight after it is forced through the polycarbonate filters.

Rp = pore size of barrier.

rv = vesicle size after extrusion.

4.4 Transmission electron microscopy (TEM)

In order to visualize the vesicles, TEM was used. The sample for the TEM is prepared using one waterless PTA (phosphotungstic acid) and traditional negative-staining techniques. A drop containing vesicles was dried for staining on a carbon-carpeted copper surface, and the excess was removed with sludge paper. The instance appears as a tiny, concave vesicle with girdling darkness after drying [51, 52]

4.5 Fourier Transforms Infrared Spectroscopy and Differential Scanning Calorimetry

A study using discriminational calorimetry surveying was conducted to investigate the thermal gets of the colorful lipid vesicles. To ascertain any relationships between the components of the vesicle membrane and the medication, an infrared spectroscopy study is employed [53].

4.6 In-vitro diffusion study

Using Franz diffusion cell equipment, the in vitro prolixity research of an elastic transfersome was assessed. A cellophane membrane was positioned between the patron and receptor chambers after being presoaked in phosphate buffer for a full day. In a patron cube, elastic transfersome expression is positioned on the sigma membrane. The required amount of phosphate buffer was added to the receptor cube, and it was shaken with a fancy stirrer. To ensure sink condition, the sample aliquots are removed from the receptor cube at predetermined intervals and continuously replaced with an equivalent volume of fresh phosphate buffer result. A UV-visible spectrophotometer was used to anatomize the entire sample [54].

5. Conclusion

Compared to traditional vesicular systems, transfersomes are more effective at delivering a diverse range of medicinal molecules over the skin barrier because they are ultra-deformable carriers. The primary factor causing transfersomes to be transported into the deeper epidermal layers is the bibulous grade. Crucially, transfersomes are specially engineered vesicular systems that must be fine-tuned in accordance with specific instances of targeted medications in order to attain the best possible phrasings and final pharmacological effects. Additional research on transfersomes may result in novel and potential treatment strategies for a variety of ailments.

6. References

1. Modi C.D., Bharadia P.D., "Transfersomes: New Dominants for Transdermal Drug Delivery", Am. J. PharmTech Res., 2012, 2 (3), 71-91.
2. Megh R., Sivanappan R. K., "Nano Particle Based Delivery System and Proposed Application in Agriculture Engineering Practices for Agricultural Production and Water Conservation An Interdisciplinary Approach", Apple Academic Press.,2017, 1(16), 325-348.
3. Duangjit S., Opanasopit P., Rojanarata T., Ngawhirunpat T., "Characterization and in vitro skin permeation of meloxicamloaded Liposomes versus Transfersomes", J. Drug Deliv. 2010, 1–9.

4. Aggarwal N., Goindi S., “Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of *Microsporum canis* Dermatophytosis”, *Int. J. Pharm.*, 2012, 437,277–287.
5. Chen J., Lu W.-L., Gu W., Lu S.-S., Chen Z.-P., Cai B.-C., “Skin permeation behavior of elastic liposomes: Role of formulation ingredients”, *Expert Opin. Drug Deliv.*, 2013, 10,845–856.
6. Duangjit S., Opanasopit P., Rojanarata T., Ngawhirunpat T., “Effect of edge activator on characteristic and in vitro skin permeation of meloxicam loaded in elastic liposomes”, *Adv. Mater. Res.*, 2011, 194, 537–540.
7. Jacob L., Anoop K.R., “A review on surfactants as edge activators in ultradeformable vesicles for enhanced skin delivery”, *Int. J. Pharma Bio Sci.*, 2013, 4, 337–344.
8. Kim B., Cho H.-E., Moon S.H., Ahn H.-J., Bae S., Cho H.-D., An S., “Transdermal delivery systems in cosmetics”, *Biomed. Dermatol.*, 2020, 4, 1–12.
9. Cevc G., “Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery”, *Crit. Rev. Ther. Drug Carr. Syst.*, 1996, 13,257–388.
10. Pawar A.Y., Jadhav K.R., Chaudhari L.H., “Transfersome: A novel technique which improves transdermal permeability”, *Asian J. Pharm.*, 2016, 10,425–436.
11. Ghai I., Chaudhary H., Ghai S., Kohli K., Kr V., “A review of transdermal drug delivery using nano-vesicular carriers: Transfersomes”, *Recent Pat. Nanomed.*, 2012, 2,164–171.
12. Modi C., Bharadia P., “Transfersomes: New dominants for transdermal drug delivery”, *Am. J. PharmTech. Res.*, 2012, 2,71–91.
13. Li J., Wang X., Zhang T., Wang C., Huang Z., Luo X., Deng Y., “A review on phospholipids and their main applications in drug delivery systems”, *Asian J. Pharm. Sci.*, 2015, 10,81–98.
14. Moawad F.A., Ali A.A., Salem H.F., “Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of Tizanidine HCl: Preparation, in vitro and in vivo performance”, *Drug Deliv.*, 2017, 24,252–260.
15. Bnyan R., Khan I., Ehtezazi T., Saleem I., Gordon S., Neill F.O., Roberts M., “Surfactant effects on lipid-based vesicles properties”, *J. Pharm. Sci.*, 2018, 107,1237–1246.
16. Kumar A., “Transferosome: A recent approach for transdermal drug delivery”, *J. Drug Deliv. Ther.*, 2018, 8,100–104.
17. MirAfzali Z., Thompson C.S., Tallua K., “Microencapsulation in the Food Industry: A Practical Implementation Guide”, Chapter 13—Application of liposomes in the food industry, Academic Press, Cambridge, MA, USA, 2014,139–150.
18. Grit M., Crommelin D.J., “Chemical stability of liposomes: Implications for their physical stability”, *Chem. Phys. Lipids*, 1993, 64,3–18.
19. Iskandarsyah, Rahmi A.D., Pangesti D.M., “Comparison of the characteristics of transfersomes and protransfersomes containing azelaic acid”, *J. Young-Pharm.*, 2018, 10, S11–S15.
20. Van Hoogevest P., Wendel A., “The use of natural and synthetic phospholipids as pharmaceutical Excipients”, *Eur. J. Lipid Sci. Technol*, 2014, 116, 1088–1107.
21. Yadav D., Sandeep K., Pandey D., Dutta R.K., “Liposomes for drug delivery”, *J. Biotechnol. Biomater*, 2017, 7,1–8.
22. Mathur M., “Approaches for improving the pharmacological and pharmacokinetics properties of herbal drugs”, *Int. Res. J. Pharm. Appl. Sci.*, 2013, 3,40–50.

23. Jadupati M., Kumar N.A., “Transfersome: An opportunistic carrier for transdermal drug delivery system”, *Int. Res. J. Pharm.*, 2012, 3,35–38.
24. Cevc G., Blume G., Schätzlein A., Gebauer D., Paul A., “The skin: A pathway for systemic treatment with patches and lipidbased agent carriers”, *Adv. Drug Deliv. Rev.*, 1996, 18,349–378.
25. Chaurasiya P., Ganju E., Upmanyu N., Ray S.K., Jain P., “Transfersomes: A novel technique for transdermal drug delivery”, *J. Drug Deliv. Ther.*, 2019, 9,279–285.
26. Cevc G., “Transdermal drug delivery of insulin with ultradeformable carriers”, *Clin. Pharmacokinet.*, 2003, 42,461–474.
27. Mandal U.K., Mahmood S., Taher M., “Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application”, *Int. J. Nanomed.*, 2014, 9, 4331– 4346.
28. Kumar G.P., Rajeshwarrao P., “Nonionic surfactant vesicular systems for effective drug delivery- An overview”, *Acta Pharm. Sin. B.*, 2011, 1,208–219.
29. Cipolla D., Wu H., Gonda I., Eastman S., Redelmeier T., Chan H.-K., “Modifying the release properties of liposomes toward personalized medicine”, *J. Pharm. Sci.*, 2014, 103,1851–1862.
30. Dudhipala N., Mohammed R.P., Youssef A.A.A., Banala N., “Effect of lipid and edge activator concentration on development of Aceclofenac loaded transfersomes gel for transdermal application: In vitro and ex vivo skin permeation”, *Drug Dev. Ind. Pharm.*, 2020, 46,1–28.
31. Jiang T., Wang T., Li T., Ma Y., Shen S., He B., Mo R., “Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma”, *ACS Nano.*, 2018,12,9693–9701.
32. Iskandarsyah, Rahmi A.D., Pangesti D.M., “Comparison of the characteristics of transfersomes and protransfersomes containing azelaic acid”, *J. Young-Pharm.*, 2018, 10,S11–S15.
33. Jain A.K., Kumar F., “Transfersomes: Ultradeformable vesicles for transdermal drug delivery”, *Asian J. Biomater. Res.*, 2017,3,1–13.
34. Rajan R., Jose S., Mukund V.P.B., Vasudevan D.T., “Transfersomes-A vesicular transdermal delivery system for enhanced drug permeation”, *J. Adv. Pharm. Technol. Res.*, 2011, 2,138–143.
35. Jiang T., Wang T., Li T., Ma Y., Shen S., He B., Mo R., “Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma”, *ACS Nano.*, 2018,12,9693–9701.
36. Kotla N.G., Chandrasekar B., Rooney P., Sivaraman G., Larranaga A., Krishna K.V., Pandit A., Rochev Y., “Biomimetic lipid-based nanosystems for enhanced dermal delivery of drugs and bioactive agents”, *ACS Biomater. Sci. Eng.*, 2017, 3, 1262– 1272.
37. Ascenso A., Batista C., Cardoso P., Mendes T., Praça F.G., Bentley M.V.L.B., Raposo S., Simoes S., “Development, characterization, and skin delivery studies of related ultradeformable vesicles: Transfersomes, ethosomes, and transethosomes”, *Int. J. Nanomed.*, 2015, 10,5837–5851.
38. Pawar A.Y., Jadhav K.R., Chaudhari L.H., “Transfersome: A novel technique which improves transdermal permeability”, *Asian J. Pharm.*, 2016, 10,425–436.
39. Garg V., Singh H., Bimbrawh S., Singh S.K., Gulati M., Vaidya Y., Kaur P., “Ethosomes and transfersomes: Principles, perspectives and practices”, *Curr. Drug Deliv.*, 2016, 14,613–633.
40. Kadu S.D.P., “Transfersomes—A boon for transdermal delivery”, *Indo Am. J. Pharm. Sci.*, 2017, 4, 2908–2919.

41. El Zaafarany G.M., Awad G.A.S., Holayel S.M., Mortada N., “Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery”, *Int. J. Pharm.* 2010, 397,164–172.
42. Sharma V., Yusuf M., Pathak K., “Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics”, *Int. J. Pharm. Investig.*, 2014, 4,119–130.
43. Yang Y., Ou R., Guan S., Ye X., Hu B., Zhang Y., Lu S., Zhou Y., Yuan Z., Zhang J., “A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use. *Drug Deliv.*” 2014, 22,1–8.
44. Balata G.F., Faisal M.M., Elghamry H.A., Sabry S.A., “Preparation and characterization of ivabradine HCl transfersomes for enhanced transdermal delivery”, *J. Drug Deliv. Sci. Technol.*, 2020, 60,101-121.
45. Cevc G., “Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery”, *Crit. Rev. Ther. Drug Carr. Syst.*, 1996, 13, 257–388.
46. Chauhan P., Tyagi B.K., “Herbal novel drug delivery systems and transfersomes”, *J. Drug Deliv. Ther.*, 2018, 8,162–168.
47. Qushawy M., Nasr A., Abd-Alhaseeb M., Swidan S., “Design, optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. *Pharmaceutics*”, 2018, 10-26.
48. Ahad A., Al-Saleh A.A., Al-Mohizea A.M., Al-Jenoobi F.I., Raish M., Yassin A.E.B., Alam M.A., “Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate”, *Saudi Pharm. J.*, 2017, 25,1040–1046.
49. Bnyan R., Khan I., Ehtezazi T., Saleem I., Gordon S., O’Neill F., Roberts M., “Formulation and optimisation of novel transfersomes for sustained release of local anaesthetic”, *J. Pharm. Pharmacol.*, 2019, 71,1508–1519.
50. Jain A.K., Kumar F., “Transfersomes: Ultradeformable vesicles for transdermal drug delivery”, *Asian J. Biomater. Res.*, 2017, 3,1–13.
51. Hadidi N, Saffari M, Faizi M., “Optimized transferosomal bovine lactoferrin (BLF) as a promising novel non-invasive topical treatment for genital warts caused by human papiloma virus (HPV) Iran. *J. Pharm. Res.*, 2018, 17,12–23.
52. Guo F, Wang J, Ma M, Tan F, Li N., “Skin targeted lipid vesicles as novel nano-carrier of ketoconazole : characterization , in vitro and in-vivo evaluation”, *J. Mater. Sci. Mater. Med.*, 2015, 26,1–13.
53. Abdellatif AMM, Khalil IA, Khalil AF., “Sertaconazole nitrate loaded nanovesicular systems for targeting skin fungal infection: in-vitro, ex-vivo and in-vivo evaluation”, *Int. J. Pharm.*,2017, 5,27,1–11.
54. Ganem A, Quintanar D, Nava G, Mendoza N, Mendoza L, Pinion E., “Formulation and in-vitro, ex-vivo and in-vivo evaluation of elastic liposomes for transdermal delivery of ketorolac tromethamine”, *Pharmaceutics*, 2011, 3, 954–70.